Promoters for Glaucoma Gene Therapy
About the Research Project
Program
Award Type
Standard
Award Amount
$49,986
Active Dates
April 01, 1999 - March 31, 2001
Grant ID
G1999005
Summary
Gene therapy may prove to be an ideal form of treatment for diseases with genetic causes because a normal version of a gene could be introduced into cells to restore functions that have been disrupted due to the genetic mutation. If gene therapy is to be used one day for treating forms of glaucoma, two requirements must be met. First, one needs an efficient means, or vector, for placing genes in eye tissues. Second, genetic elements called promoters are required that will allow the therapeutic gene to be specifically turned on in the appropriate cell type (e.g. TM cells). Dr. Brandt has already attained the first goal and is now focused on identifying TM cell-specific promoters.
Related Grants
National Glaucoma Research
Activating the Eye’s Own Nitric Oxide to Fight Glaucoma
Active Dates
July 01, 2026 - June 30, 2028
Principal Investigator
Myoungsup Sim, PhD
Current Organization
Duke University School of Medicine
Activating the Eye’s Own Nitric Oxide to Fight Glaucoma
Active Dates
July 01, 2026 - June 30, 2028
Principal Investigator
Myoungsup Sim, PhD
Current Organization
Duke University School of Medicine
National Glaucoma Research
Spatial Responses to Elevated Pressure in the Human Optic Nerve Head
Active Dates
July 01, 2026 - June 30, 2028
Principal Investigator
Jeremy Sivak, PhD
Current Organization
University Health Network
Spatial Responses to Elevated Pressure in the Human Optic Nerve Head
Active Dates
July 01, 2026 - June 30, 2028
Principal Investigator
Jeremy Sivak, PhD
Current Organization
University Health Network
National Glaucoma Research
Foot-Based Monitoring and Feedback to Improve Mobility and Reduce Falls in Glaucoma
Active Dates
July 01, 2026 - June 30, 2028
Principal Investigator
Navid Amini, PhD
Current Organization
California State University, Los Angeles
Foot-Based Monitoring and Feedback to Improve Mobility and Reduce Falls in Glaucoma
Active Dates
July 01, 2026 - June 30, 2028
Principal Investigator
Navid Amini, PhD
Current Organization
California State University, Los Angeles